Recombinant human anti-EGFR mAB (Genrix Bio)

重组全人源抗EGFR单克隆抗体 (智翔医药)

Report date: 2022/06/27 20:00:35

Base Information

Drug NameRecombinant human anti-EGFR mAB (Genrix Bio)
Drug Alias Name重组全人源抗EGFR单克隆抗体注射液 (智翔医药)Recombinant fully human anti-EGFR mAb (Genrix Bio)Recombinant human anti-EGFR monoclonal antibody (Genrix Bio)重组全人源抗EGFR单抗注射液 (智翔医药)GR-1401 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesShanghai Zhonghe Medicine Technology Co LtdBioex Therapeutics
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A